2026-10-25
InnovAge clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
NAS100 28,225 −4.00%
S&P 7,559 −2.10%
GOLD $3,890 −3.51%
BTC $76,928 −1.09%
VIX 21.40 +24.42%
latest tape · as of 18:03 UTC
The Screen · Healthcare · Medical Care Facilities
InnovAge Holding Corp.
INNV · Nasdaq · USD · Market cap $1.3B · 2,440 employees
InnovAge Holding Corp.
Not yet scored9.55 USD
Price as of 23 Oct 2026Daily close, not a live quoteLast reviewed 7 days ago
Screened 2026-10-23 · the tape above runs as of 18:03 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price9.55 USD at the 23 Oct 2026 close
- Ethical screenNot yet scored
- OptionsOpen interest leans heavily to calls (put/call 0.01)
- Last reviewed23 Oct 2026 (7 days ago)
A summary of the dated readings below, not a live quote and not advice.
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 9.55 against the desk's fair-value range, base estimate 11.20, over the last year.
- Trend Accumulation
- Insiders insiders sold, $32,353, latest filing 2026-10-22
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 0.01, read 2026-10-29
- Ethical screen not yet scored
Price9.55 USD
Fair value11.20
Ethical score70.0/100
Our investment reviews on this name
2026-10-25Read Accumulation9.52+0.3% to today ✓Markdown gives way to Accumulation after a 6% rise in 2 weeks
2026-10-11Read Markdown9.00+6.1% to today Distribution gives way to Markdown after a 15% slide in 9 days
2026-10-02Read Distribution10.60-9.9% to today ✓Markdown gives way to Distribution with volume flow in agreement
2026-09-02Read Markdown10.83-11.8% to today ✓Markup gives way to Markdown after a 6% slide in 4 weeks
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
The full research record, in depth, below
This name holds its accumulation label.
InnovAge Holding Corp. holds its Accumulation at $9.55. The statistical read favours the buyers, held for 2 days.
| Phase | Accumulation |
| Quantitative state | The statistical read favours the buyers, held for 2 days |
| Price at the screen | $9.55 |
| Valuation | N/A trailing · 19.04 forward price to earnings |
| Values screen | Not scored · score 70.0 |
| Beta | 0.15 |
Five Screens, Shown in Full
This security has not been fully scored against the values screen yet.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 19.19% | Below 33% | Interest-bearing debt is just 19.2% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 7.93% | Below 33% | Cash held in interest-bearing accounts and securities is 7.9% of assets, under the one-third limit. | Pass |
| Receivables | 19.08% | Below 49% | Money owed to the company is 19.1% of assets, under the 49% limit. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadThe Read, in Plain English
InnovAge clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
Read as at 2026-10-29. It updates when the underlying figures move, and past reads are kept below.
2026-09-24
Clears
InnovAge clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 19%, inside the ~33% line, and almost none of its income is interest, so it passes.
Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.
What the Numbers Say It Is WorthThe Fair Value Range
Fair value range in USD, drawn from the 2026-10-23 screen. The gold marker is the market price at the same screen. A 17.3% margin of safety to the base estimate.
Third-party analyst targets: 2 covering, consensus None. The average target sits +26% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & ProjectionsWhere it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-23 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsSeniors Care Operator Priced Far Beyond Its Numbers
Picture an elderly parent relying on all-inclusive day programmes to stay at home rather than enter a nursing facility. InnovAge runs exactly those PACE centres, yet it still reports a negative profit margin and a negative return on equity while revenue grows at 16 percent. The shares sit at 11.50 dollars against our fair value of 7 dollars, a 39 percent premium that leaves no room for error.
We pass because the valuation already prices in flawless execution that the current numbers do not support. A 30 times forward earnings multiple on a business that is losing money looks optimistic even before considering the single-analyst target also sits at 7 dollars. Ethical screens clear, yet the opportunity rating remains none.
High multiples on unprofitable operations create the main risk here. Any slowdown in enrolment or rise in medical costs would widen losses quickly and could trigger a sharp reset in the share price. Analysis, not advice.
| Forward P/E | 19.0xfairly priced for its growth rate |
| EPS, trailing | -0.02 |
| EPS, forward | 0.50 |
| Revenue growth | +18.3%steady growth |
| Profit margin | -0.3%currently unprofitable |
| Return on equity | -0.3%not currently earning a positive return on equity |
| FCF yield | 3.81% |
| Debt to equity | 0.32minimal debt: a conservative balance sheet |
| Current ratio | 1.05adequate liquidity, worth monitoring |
| Beta | 0.15barely tracks the market's swings |
| Short interest, float | 0.12% |
| 52-week range | 3.94 - 12.64 |
| Market cap | $1.3B |
| Employees | 2,440 |
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeINNV trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
2026-10-30
Accumulation $9.55
+0.0% Entry 16
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 6% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 114%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (1 analysts) rates it none, with a mean price target of $7. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29
Accumulation $9.55
+0.3% Entry 15
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.3% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 6% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 114%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (1 analysts) rates it none, with a mean price target of $7. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28
Accumulation $9.52
+0.0% Entry 14
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 6% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 114%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (1 analysts) rates it none, with a mean price target of $7. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27
Accumulation $9.52
+0.0% Entry 13
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 6% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 114%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (1 analysts) rates it none, with a mean price target of $7. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25
Accumulation · changed $9.52
+6.0% Entry 12
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 6.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 0% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 114%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (1 analysts) rates it none, with a mean price target of $7. Insiders have been net sellers over the past quarter.
2026-10-18
Markdown $8.98
-0.2% Entry 11
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.2% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 20% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 114%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (1 analysts) rates it none, with a mean price target of $7. Insiders have been net sellers over the past quarter.
2026-10-11
Markdown · changed $9.00
-15.1% Entry 10
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 15.1% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 20% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 114%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (1 analysts) rates it none, with a mean price target of $7. Insiders have been net sellers over the past quarter. Since the last review it its composite score rose.
2026-10-02
Distribution · changed $10.60
-2.1% Entry 9
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 2.1% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 20% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 114%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (1 analysts) rates it none, with a mean price target of $7. Insiders have been net sellers over the past quarter. Since the last review it its composite score rose.
2026-09-08
Markdown $10.83
+0.0% Entry 8
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 20% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 114%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (1 analysts) rates it none, with a mean price target of $7. It reported earnings in this window, a natural checkpoint for the thesis.
2026-09-06
Markdown $10.83
+0.0% Entry 7
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 20% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 114%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (1 analysts) rates it none, with a mean price target of $7. It reported earnings in this window, a natural checkpoint for the thesis.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- California Healthcare Stocks Tied To State Funding And Senior Care Demand Yahoo Finance · 6d ago
- InnovAge to Announce Fiscal First Quarter 2027 Financial Results and Host Conference Call Tuesday, November 3, 2026 Yahoo Finance · 10d ago
- InnovAge Holding (INNV), Why Is It Getting Fresh Attention? Yahoo Finance · 27 Sep 2026
- InnovAge Announces Pricing of Secondary Offering of Common Stock by Selling Stockholders Yahoo Finance · 23 Sep 2026
- InnovAge Announces Launch of Proposed Secondary Offering of Common Stock by Selling Stockholders Yahoo Finance · 22 Sep 2026
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
USPHU.S. Physical Therapy, Inc.
NUTXNutex Health Inc.
PNTGThe Pennant Group, Inc.
AGLagilon health, inc.
PIIIP3 Health Partners Inc
CMPSCOMPASS Pathways plc
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-22 | Damato Nicole | GC | S - Sale | 3,402 | $32,353 |
| 2026-10-21 | Welsh, Carson, Anderson & Stowe Xii, L.P. | 10% | S - Sale | 1,500,000 | $13,875,000 |
| 2026-10-21 | Ignite Aggregator LP | 10% | S - Sale | 1,500,000 | $13,875,000 |
| 2026-10-21 | Tco Group Holdings, L.P. | 10% | S - Sale | 1,500,000 | $13,875,000 |
| 2026-09-25 | Damato Nicole | GC | S - Sale | 23,814 | $207,182 |
| 2026-09-24 | Tco Group Holdings, L.P. | 10% | S - Sale | 10,000,000 | $92,500,000 |
| 2026-09-24 | Ignite Aggregator LP | 10% | S - Sale | 10,000,000 | $92,500,000 |
| 2026-09-24 | Welsh, Carson, Anderson & Stowe Xii, L.P. | 10% | S - Sale | 10,000,000 | · |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $7.36 | +10.6% | · | $1,106 | +10.6% |
| 2 months | $8.20 | -0.7% | · | $993 | -0.7% |
| 3 months | $8.33 | -2.3% | · | $977 | -2.3% |
| 6 months | $5.36 | +51.9% | · | $1,519 | +51.9% |
| 1 year | $3.81 | +113.7% | · | $2,137 | +113.7% |
| 2 years | $4.97 | +63.8% | · | $1,638 | +63.8% |
| 3 years | $7.50 | +8.5% | · | $1,085 | +8.5% |
| 5 years | $21.25 | -61.7% | · | $383 | -61.7% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever INNV does next, these words stay.
Membership
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.